MedTrace Logo

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study

NCT01139476 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1892

Last updated 2026-05-01

No results posted yet for this study

Summary

Background:

\- Multiple myeloma (MM), a type of cancer that affects the white blood cells, is often preceded by a precancerous disorder known as monoclonal gammopathy of undetermined significance (MGUS). Farmers and other agricultural workers have a higher risk of developing MGUS and MM, possibly because of their exposure to certain pesticides. Researchers are interested in studying biological specimens taken from participants in the Agricultural Health Study - specifically, pesticide applicators at least 50 years of age who do not have cancer- to better understand the development of MGUS and MM.

Objectives:

* To collect biological specimens from Agricultural Health Study participants for further research.
* To examine the relationship between pesticide exposure and MGUS/MM.

Eligibility:

\- Male pesticide applicators who are over 50 years of age, cancer-free, and participating in the Agricultural Health Study.

Design:

* Two groups of participants will complete the study: a general group and a smaller group of individuals who have been exposed to the pesticide diazinon.
* All participants will receive an initial contact letter with information about the study, followed by a phone call to administer a screening questionnaire and arrange a home visit from a researcher within the next month.
* Participants will receive by mail a urine specimen kit that will be collected at the home visit.
* During the home visit, a study researcher will take blood samples and collect the urine sample, and will administer another questionnaire.
* Participants in the group exposed to diazinon will have three home visits for the study: (1) prior to pesticide exposure, (2) the day after participants stop using diazinon, and (3) about 21 days after the second visit. The first visit will take place in the off-season from January to March; the second and third visits will be conducted between April and August.
* No treatment will be provided as part of this study.

Conditions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Jonathan N Hofmann, Ph.D. · National Cancer Institute (NCI)

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01139476 on ClinicalTrials.gov